ABSTRACT
Purpose Efficient and scalable solutions are needed to identify patients who qualify for germline cancer genetic testing. We evaluated the clinical validity of a brief, patient-administered hereditary cancer risk assessment digital tool programmed to assess if patients meet criteria for germline genetic testing, based on personal and family history, and in line with national guidelines.
Methods We applied the tool to cases seen in a nationwide telehealth genetic counseling practice. Validity of the tool was evaluated by comparing the tool’s assessment to that of the genetic counselor who saw the patient. Patients’ histories were extracted from genetic counselor-collected pedigrees and input into the tool by the research team to model how a patient would complete the tool. We also validated the tool’s assessment of which specific aspects of the personal and family history met criteria for genetic testing.
Results Of the 152 cases (80% ((121/152)) female, mean age 52.3), 56% (85/152) had a personal history of cancer and 66% (99/152) met genetic testing criteria. The tool and genetic counselor agreed in 96% (146/152) of cases. Most disagreements (4/6; 67%) occurred because the GC’s assessment relied on details the tool was not programmed to collect since patients typically don’t have access to the relevant information (pathology details, risk models). We also found complete agreement between the tool and research team on which specific aspects of the patient’s history met criteria for genetic testing.
Conclusion We observed a high level of agreement with genetic counselor assessments, affirming the tool’s clinical validity in identifying individuals for hereditary cancer predisposition testing and its potential for increasing access to hereditary cancer risk assessment.
Competing Interest Statement
CR, AD, DV, AH, KJ, JD, HC, CA, MS, CC declare employment at Genome Medical; AD, DV, AH, KJ, JD, HC, CA, MS, CC declare stock and/or stock options in Genome Medical; KJ, JD, MS declare leadership in Genome Medical; CR, AD, DV, AH, KJ, JD, KR, CA, MS, CC declare a patent pending on technology underpinning the digital tool that is the focus of this article; KR declares stock options in Stata Oncology; DV declares employment, ownership interest, and consulting with Call Light Health.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
WIRB-Copernicus Group Institutional Review Board deemed this work exempt and approved a waiver of authorization for use and disclosure of protected health information (PHI) because the study analyzed deidentified secondary data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
